Clinical trial NCT03572556: Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)
Official title: Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hereditary Hemorrhagic Telangiectasia
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2018-06-28
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: outpatient

Brief summary: Hereditary hemorrhagic telangiectasia (HHT) results from genetic deregulation of angiogenesis. It is characterized by mucocutaneous telangiectasia responsible for recurrent epistaxis affecting quality of life (anaemia, iron deficiency, social distress). More rarely, HHT is complicated by the appearance of pulmonary, hepatic or cerebral arteriovenous malformations that can lead to serious complications: cerebrovascular accidents, cerebral abscesses, high output heart failure, and massive hemoptysis (1). The intensity of symptoms increases with age but with significant individual variability, even for the same mutation in the same family. Thus, while the mutations responsible for the disease have been identified, the pathophysiology is not fully understood because these mutations do not explain the great diversity of clinical presentations. Other factors not yet identified probably play an important role. Angiogenic T cells (TANG) are a newly individualized T cell population, defined by a CD4+CXCR4+CD31+ phenotype, which plays a key role in differentiating endothelial progenitors (2).

In an earlier study, the investigators showed that patients with HHT had a decrease in CD4+ and CD8+ LT compared to a cohort of healthy subjects (3).

They hypothesize that the lymphopenia mainly involves TANG, whose quantification could make it possible to assess the individual level of angiogenesis during HHT. The evaluation of the TANG levels could thus make it possible to personalize HHT management.


Eligibility criteria: Inclusion Criteria:

* Person who has given consent
* Adult
* Person capable of understanding spoken and written French

"Patient" group:

* Certain HHT (3 or 4 Curacao criteria - Appendix 2):
* Recurring epistaxis
* Telangiectasia of the skin or mouth
* Family hereditary context
* Arteriovenous visceral malformations
* Causal mutation identified
* Person capable of completing monthly epistaxis charts

"Control" group :

- Control subjects will be matched to patients for age (+/- 6 years) and sex.

Exclusion Criteria:

* Person not affiliated to a national health insurance scheme
* Pregnant or breastfeeding woman
* Protected adult
* Hemoglobin levels less than 9 g/dl in the last 15 days
* Progressive or recent infectious disease, autoimmune disease or cancer (less than 6 months)
* Immunosuppressive treatment in progress or recent (less than 6 months), including systemic steroid therapy. The use of inhaled or topical steroids is not an exclusion criterion.
* Treatment in progress or stopped less than 6 months ago or to be introduced within the next 3 months of the following medications:

  * bevacizumab
  * tranexamic acid
  * dipeptidyl peptidase 4 inhibitors (diabetic patient)
  * beta-blockers (hypertensive patient)

Primary outcomes:
measure: Average monthly duration (in minutes) of epistaxis over the 3 months following inclusion
timeFrame: Through study completion, an average of 3 months
measure: Number/mm3 of circulating TANG (CD3+CXCR4+CD31+) at inclusion.
timeFrame: At inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: CHU Dijon Bourgogne
Study officials:
References: